Silver Book Fact

Reducing risk of fracture from 8% to 2% reduces the 5-year fracture incidence from approximately 34% to 10%.

Lindsay, Robert, Simon Pack, and Li Zhengqing. Longitudinal Progression of Fracture Prevalence through a Population of Postmenopausal Women with Osteoporosis. Osteoporos Int. 2005; 16(3): 306-12. http://www.ncbi.nlm.nih.gov/pubmed/15455193

Reference

Title
Longitudinal Progression of Fracture Prevalence through a Population of Postmenopausal Women with Osteoporosis
Publication
Osteoporos Int
Publication Date
2005
Authors
Lindsay, Robert, Simon Pack, and Li Zhengqing
Volume & Issue
Volume 16, Issue 3
Pages
306-12
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • A recent study found that more postmenopausal women who took the drug denosumab gained at least 3% of bone mass at the hip and spine than those who took…  
  • A meta-analysis of clinical trials found that Vitamin D supplements reduced the risk of vertebral fractures by around 37%.  
  • Alendronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by as much as 8% over 3-years in postmenopausal women with osteoporosis.  
  • Alendronate, a bisphosphonate, has been shown to reduce risk of hip fracture by around 53%, clinical vertebral fracture by 45%, and wrist fracture by 30%.  
  • Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.